SpringWorks eyes US filing for MEK inhibitor after positive PhIIb data in rare disease
SpringWorks Therapeutics has unveiled positive data from a mid-stage trial of its drug candidate for neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN), paving the way for a US filing and potential priority review next year.
The Phase IIb ReNeu trial studied mirdametinib in 114 subjects aged two years and older with inoperable NF1-associated PNs and resulting significant morbidity. The trial’s primary endpoint was objective response rate, which was defined as a minimum 20% reduction in target tumor volume. Topline data showed that 52% of children and 41% of adults achieved this measure.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.